Deferasirox (Exjade®) significantly improves cardiac T2* in heavily iron-overloaded patients with β-thalassemia major

Annals of Hematology

Volumn 89, Issue 4, 2010, Pages 405-409

  Pathare, Anil ^a   Taher, Ali ^b   Daar, Shahina ^c  

^a SULTAN QABOOS UNIVERSITY HOSPITAL   (Oman)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^c SULTAN QABOOS UNIVERSITY   (Oman)

Author keywords

thalassemia; Iron chelation; Iron overload; Magnetic resonance imaging; Myocardial iron; T2*

Indexed keywords

DEFERASIROX; FERRITIN; IRON; BENZOIC ACID DERIVATIVE; IRON CHELATING AGENT; TRIAZOLE DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRY WEIGHT; FEMALE; FERRITIN BLOOD LEVEL; HEART HEMOSIDEROSIS; HUMAN; IRON OVERLOAD; LIVER LEVEL; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; THALASSEMIA MAJOR; TREATMENT DURATION; BETA THALASSEMIA; BLOOD; HEART DISEASE; LIVER; METABOLISM; PATHOPHYSIOLOGY;

ADOLESCENT; ADULT; BENZOIC ACIDS; BETA-THALASSEMIA; CHILD; FEMALE; FERRITINS; HEART DISEASES; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; LIVER; MAGNETIC RESONANCE IMAGING; MALE; TRIAZOLES; YOUNG ADULT;

EID: 77649296214     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-009-0838-z     Document Type: Article

References (21)

1. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW (1994) Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 331:567-573
2. Zurlo MG, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melevendi C, Di Gregorio F, Burattini MG, Terzoli S (1989) Survival and causes of death in thalassaemia major. Lancet 2:27-30
3. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, Romeo MA, Forni GL, Gamberini MR, Ghilardi R, Piga A, Cnaan A (2004) Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 89:1187-1193
4. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, Firmin DN, Wonke B, Porter J, Walker JM, Pennell DJ (2001) Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 22:2171-2179
5. Wood JC, Otto-Duessel M, Aguilar M, Nick H, Nelson MD, Coates T, Moats R, Coates TD (2004) Cardiac MRI (T2, T2) predicts cardiac iron in the gerbil model of iron cardiomyopathy. Blood 104(11):376 abst
6. CappelliniMD, Cohen A, Piga A, BejaouiM, Perrotta S, Agaoglu L, Aydinok Y, Kattamis A, KilincY, Porter J, Capra M,Galanello R et al (2006) A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood 107:3455-3462
7. Porter J, Galanello R, Saglio G, Neufeld EJ, Vichinsky E, Cappellini MD, Olivieri N, Piga A, Cunningham MJ, Soulières D, Gattermann N, Tchernia G et al (2008) Relative response of patients with myelodysplastic syndromes and other transfusiondependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol 80:168-176
8. Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Eckman J, Lane P, Files B, Hassell K, Kelly P, Wilson F, Bernaudin F, Forni GL et al (2007) A randomized comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 136:501-508
9. Wood JC, Otto-DuesselM,Gonzales I,AguilarMI, Shimada H, Nick H, Nelson M, Moats R (2006) Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil. Transl Res 148:272-280
10. Eleftheriou P, Tanner M, Pennell D, Porter JB (2006) Response of myocardial T2* to oral deferasirox monotherapy for 1 year in 29 patients with transfusion- dependent anaemias; a subgroup analysis. Haematologica 91(Suppl 1):999 abst
11. Wood JC, Thompson AA, Paley C, Kang B, Giardina P, Harmatz P, Virkus J, Coates TD (2008) Deferasirox (Exjade®) monotherapy significantly reduces cardiac iron burden in chronically transfused β-thalassemia patients: an MRI T2* study. Blood 112 (11):3882 abst
12. Pennell D, Porter JB, Cappellini MD, Li C-K, Aydinok Y, Lee Lee C, Kattamis A, Smith G, Habr D, Domokos G, Hmissi A, Taher A (2008) Efficacy and safety of deferasirox (Exjade®) in reducing cardiac iron in patients with β-thalassemia major: results from the cardiac substudy of the EPIC trial. Blood 112(11):3873 abst
13. Pennell D, Sutcharitchan P, El-Beshlawy A, Aydinok Y, Taher A, Smith G, Habr D, Kriemler-Krahn U, Hmissi A, Porter JB (2008) Efficacy and safety of deferasirox (Exjade®) in preventing cardiac iron overload in β-thalassemia patients with normal baseline cardiac iron: results from the cardiac substudy of the EPIC trial. Blood 112(11):3874 abst
14. Garbowski M, Eleftheriou P, Pennell D, Tanner M, Porter JB (2008) Impact of compliance, ferritin and LIC on long-term trends in myocardial T2* with deferasirox. Blood 112(11):116 abst
15. Taher A, El-Beshlawy A, Elalfy MS, Al Zir K, Daar S, Damanhouri G, Habr D, Kriemler-Krahn U, Hmissi A, Al Jefri A (2009) Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study. Eur J Haematol 82(6):458-465
16. Westwood M, Anderson LJ, Firmin DN, Gatehouse PD, Charrier CC, Wonke B, Pennel DJ (2003) A single breath-hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging 18(1):33-39
17. St. Pierre TG, Clark PR, Chua-anusorn W, Fleming AJ, Jeffrey GP, Olynyk JK, Pootrakul P, Robins E, Lindeman R (2005) Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 105(2):855-861 (Pubitemid 40070775)
18. Noetzli LJ, Carson SM, Nord AS, Coates TD, Wood JC (2008) Longitudinal analysis of heart and liver iron in thalassemia major. Blood 112:2973-2978
19. Kolnagou A, Economides C, Eracleous E, Kontoghiorghes GJ (2006) Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*. Hemoglobin 30(2):219-227
20. Anderson LJ, Westwood MA, Prescott E, Walker JM, Pennell DJ, Wonke B (2006) Development of thalassaemic iron overload cardiomyopathy despite low liver iron levels and meticulous compliance to desferrioxamine. Acta Haematol 115 (1-2):106-108
21. Daar S, Pathare AV, Jain R, Zadjali SA, Pennell DJ (2009) T2* cardiovascular magnetic resonance in the management of thalassemia patients in Oman. Haematologica. 94(1):140-141